Development of a disease-specific version of the EQ-5D-5L for use in patients suffering from psoriasis: Lessons learned from a feasibility study in the UK

Value in Health

Volumn 16, Issue 8, 2013, Pages 1156-1162

  Swinburn, Paul ^a   Lloyd, Andrew ^a   Boye, K S ^b   Edson Heredia, Emily ^c   Bowman, Lee ^b   Janssen, Bas ^d  

^a ICON PLC   (United Kingdom)

^b ELI LILLY AND COMPANY   (United States)

^c HEOR Janssen Consultancy   (Netherlands)

^d ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

disease specific; economic evaluation; EQ 5D; health related quality of life; instrument development; psoriasis; utilities

Indexed keywords

ARTICLE; FEASIBILITY STUDY; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PSORIASIS; PSYCHOMETRY; QUALITY OF LIFE; QUESTIONNAIRE; SELF CONCEPT; SKIN IRRITATION; UNITED KINGDOM; VALIDATION STUDY;

DISEASE-SPECIFIC; ECONOMIC EVALUATION; EQ-5D; HEALTH-RELATED QUALITY OF LIFE; INSTRUMENT DEVELOPMENT; PSORIASIS; UTILITIES;

GREAT BRITAIN; HEALTH STATUS; HUMANS; INTERPERSONAL RELATIONS; PSORIASIS; PSYCHOMETRICS; QUALITY OF LIFE; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; SELF CONCEPT;

EID: 84890310677     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2013.10.003     Document Type: Article

References (28)

1. EuroQol Group. Available from: http://www.euroqol.org/. [Accessed May 5, 2013].
2. National Institute for Clinical Excellence. Guide to the methods of technology appraisal. 2008. Available from: http://www.nice.org.uk/niceMedia/ pdf/TAP-Methods.pdf. [Accessed January 22, 2013].
3. M. Espallargues, C.J. Czoski-Murray, and N.J. Bansback The impact of age-related macular degeneration on health status utility values Investig Ophthal Vis Sci 46 2005 4016 4023
4. S. Macran, H. Weatherly, and P. Kind Measuring population health: a comparison of three generic health status measures Med Care 41 2003 218 231
5. A. Kaarlola, V. Pettilä, and P. Kekki Performance of two measures of general health-related quality of life, the EQ-5D and the RAND-36 among critically ill patients Intensive Care Med 30 2004 2245 2252
6. J. Brazier Is the EQ-5D fit for purpose in mental health? Br J Psychiatry 197 2010 348 349
7. National Institute for Health and Care Excellence. Guide to the methods of technology appraisal third edition (draft for consultation). 2012. Available from: http://www.nice.org.uk/media/CB1/43/ GuideToMethodsOfTechnologyAppraisal2012.pdf. [Accessed January 22, 2013].
8. EuroQol Group symposium. New research for future approaches to measuring and valuing health. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), 2012, Berlin, Germany.
9. P.F.M. Krabbe, M.E.A. Stouthard, and M.L. Essink-Bot The effect of adding a cognitive dimension to the EuroQol multiattribute health-status classification system J Clin Epidemiol 52 1999 293 301
10. T.V. Perneger, and D.S. Courvoisier Exploration of health dimensions to be included in multi-attribute health-utility assessment Int J Qual Health Care 23 2011 52 59
11. Yang Y, Brazier J, Tsuchiya A. The effect of adding a 'sleep' dimension to EQ-5D classification. Paper presented at Health Economist Study Group meeting (HESG), January 2008, University of East Anglia, Norwich, UK.
12. F.R. Pereira, M.K. Basra, A.Y. Finlay, and M.S. Salek The role of the EQ-5D in the economic evaluation of dermatological conditions and therapies Dermatology 225 2012 45 53
13. Longworth L, Mulhern B, Yang Y, et al. A systematic review of the performance of EQ-5D in four disease areas. Poster presented at 28th Scientific Plenary Meeting of the EuroQol Group, 2011, Oxford, UK.
14. J. Schmitt, M. Meurer, M. Klon, and K.D. Frick Assessment of health state utilities of controlled and uncontrolled psoriasis and atopic eczema: a population-based study Br J Dermatol 158 2008 351 359
15. F. Sampogna, P. Gisondi, and C.F. Melchi Prevalence of symptoms experienced by patients with different clinical types of psoriasis Br J Dermatol 151 2004 594 599
16. J. Koo Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment Dermatol Clin 14 1996 485 496
17. D.G. Fortune, H.L. Richards, and C.E.M. Griffiths Psychologic factors in psoriasis: consequences, mechanisms, and interventions Dermatol Clin 23 2005 681 694
18. M. Scharloo, A.A. Kaptein, and J. Weinman Patients' illness perceptions and coping as predictors of functional status in psoriasis: a 1 year follow up Br J Dermatol 142 2000 899 907
19. M. Young The psychological burden and social burdens of psoriasis Dermatol Nurs 17 2005 15 19
20. J. De Korte, M.A.G. Sprangers, F.M.C. Mombers, and J.D. Bos Quality of life in patients with psoriasis: a systematic literature review J Investig Dermatol Symp Proc 9 2004 140 147
21. A.K. Wahl, E. Gjengedal, and B.R. Hanestad The bodily suffering of living with severe psoriasis: in-depth interviews with 22 hospitalized patients with psoriasis Qual Health Res 12 2002 250 261
22. J. Tomforde, A. Silverman, and R. Barnes Gene for familial psoriasis susceptibility mapped to the distal end of human chromosome 17q Science 264 5162 1994 1141 1145
23. Lloyd A, Swinburn P, Edson EJ, et al. Development of the EQ-5D-Psoriasis. Proceedings of the EuroQol Plenary Meeting, 16-18 September 2010, Athens, Greece.
24. A.Y. Finlay, and G.K. Khan Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use Clin Exp Dermatol 19 1994 210 216
25. A.B. Fleischer, S.R. Rapp, and D.M. Reboussin Patient measurement of psoriasis disease severity with a structured instrument J Investig Dermatol 102 1994 967 969
26. G.W. Torrance, W. Thomas, and D. Sackett A utility maximization model for evaluation of health care programmes Health Serv Res 7 1972 118 133
27. Y. Hongbo, C.L. Thomas, and M.A. Harrison Translating the science of quality of life into practice: what do Dermatology Life Quality Index scores mean? J Invest Dermatol 125 2005 569-64
28. B. van Hout, M.F. Janssen, and Y.S. Feng Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets Value Health 15 2012 708 715